Therapeutic Pipeline

We are developing gene therapy product candidates in the retinal, metabolic and neurodegenerative therapeutic areas.

Indication Description Phase I Phase II Pivotal Approval
Retinal Disease

Wet AMD

subretinal delivery
ABBV-RGX-314


eye care collaboration
Anti-VEGF
Global regulatory submissions expected H1 2026

Wet AMD

suprachoroidal delivery

Diabetic retinopathy

suprachoroidal delivery
Neuromuscular Diseases

Duchenne

RGX-202
Novel microdystrophin
Neurodegenerative Diseases

MPS II

RGX-121
Iduronate-2-sulfatase enzyme
BLA filing in 2024